Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Clinical trial NCT01516970 · COMPLETED

Trial details

NCT number: NCT01516970
Sponsor: Janssen-Cilag G.m.b.H
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Human Immunodeficiency Virus (HIV)

Start date: 2011-11-25
Primary completion: 2013-08-01
Enrollment: 312

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.